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INTRODUCTION
Malaria is a mosquito-borne infectious disease of humans
and other animals caused by genus Plasmodium (P.).
Five Plasmodium species are known to infect humans;
Plasmodium falciparum, Plasmodium vivax, Plasmodium
malariae, Plasmodium ovale and Plasmodium knowlesi.
Of the five species, P. falciparum is the most virulent
while P. vivax is the most common causing an estimated
216 million annual infections worldwide. Approximately
2.6 billion people are at risk globally of acquiring malaria
via this species.1 Mortality rates worldwide are not
documented as yet.
Although, approximately 80 – 90% of P. vivax burden is
concentrated in the Central and South America, Middle
East and Asia,2 however, baseline data on epidemiology,
genotypes, drug resistance and pathogenesis is lacking
from key malaria endemic areas including Pakistan.
Epidemiology: Malaria poses a major public health
problem for Pakistan with an estimated 4.5 million
suspected malaria cases being reported, of which 70%
are caused by P. vivax and 30% are caused by
P. falciparum. Pakistan is one of the 6 countries within
WHO Eastern Mediterranean Region with areas of high
malaria transmission and is thus regarded as a malaria
endemic region with 100% of the population living at risk
(Figure 1).3
Nationally, on the basis of endemicity, the provinces can
be divided into three groups: high endemicity province
with average five-year Annual Parasite Incidence (API)
> 5, moderate endemicity province with average five-
year API < 5 and low endemicity province with average
five-year API < 1. According to this categorization, all the
highly endemic districts belong to Balochistan, Khyber
Pukhtunkhwa and some areas of Sindh province. Major
reasons for high malaria endemicity in these areas are
heavy monsoon rainfalls and floods, poor sanitation,
improper management of waste, poor public health care
system and high human migration influx into Sindh and
Balochistan.4 These factors provide a safe heaven for
the spread of mosquito vectors and facilitate malaria
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transmission through human parasite reservoirs,5
possibly increasing malaria burden every year in
Pakistan.
Though, a major contributor of malaria, P. vivax is a
neglected parasite species worldwide and in Pakistan6
and limited data is available on circulating genotypes,
transmissibility and prevalence of drug resistance.
Immense epidemiological significance is associated with
these aspects and need based research is required so
that baseline data could be reported. After such a data is
gathered, analyzed and reported to the Malaria Control
Program, Pakistan, steps for effective malaria control
can be taken and policies implemented in Pakistan.
To perform epidemiological studies on the population
characteristics and drug resistance patterns of P. vivax,
knowledge on the life cycle and the antigens produced
by the parasite in the human host needs to be
understood.
Life cycle: The life cycle of P. vivax includes many
transitions and stages in both mosquito and human host.
When infected Anopheles mosquito bites a human, it
releases motile sporozoites into the blood vessels which
are transported to the liver. In the liver, the sporozoites
enter the hepatocytes, initiate nuclear division and
eventually segment resulting in the formation of tens of
thousands of merozoites. The clinical disease begins
after an incubation of 1 – 4 weeks, when the infected
hepatocytes rupture and release the merozoites into
the blood stream. The asexual cycle and pathogenic
stage begins when the merozoites invade the reticulo-
cytes, develop and multiply further while ingesting the
haemoglobin. Some merozoites develop into gameto-
cytes (male and female forms) that await ingestion by
the mosquito, thus, initiating another pathogenic cycle in
a different human host.7
In P. vivax infection, frequent relapses are very common
(occurring approximately 3 – 6 weeks apart) since the
sporozoites sometimes enter a dormant, hypnozoite
stage in the liver and become active later on. Factors
that trigger the growth of these latent forms are
unknown. These relapse patterns of P. vivax are highly
significant with regard to genetic diversity, drug
resistance and disease severity. However, limited data
has been published on this aspect of P. vivax.7
Genetic diversity in Plasmodium vivax: Genetic
diversity is defined as the total number of heritable
characteristics in the genetic makeup of the species.8
Studies have shown that Plasmodium species show
diversity in several parameters including morphology,
biochemistry, relapse patterns, symptoms, course and
duration of infection, immunological responses, drug
resistance and transmissibility by anopheline vectors.
However, the extent of genetic diversity observed
depends on the transmission rates, immune pressure
and natural selection of the parasite in an area.9 Usually
in endemic areas where transmission rates are high,
extensively diverse variants are circulating posing a
threat to the public health since such variants have
possibly acquired increased virulence and resistance to
drugs in order to fit and survive.10
Majority of studies on genetic diversity of P. vivax have
been based on polymorphic markers encoding parasite
surface antigens such as circumsporozoite protein
(csp) and merozoite surface protein-1 (msp-1).11 These
antigenic genes exhibit nucleotide polymorphisms which
result in production of multiple allelic forms.12 These
alleles are capable of successfully surviving within the
host and the environment.13 Thus, knowledge of
respective allelic forms within a population helps in
understanding the origin, dispersal and stability of
various parasite genotypes and their role in drug
resistance, host immune response and effectiveness of
control strategies.13 However, due to paucity of data
from all provinces of Pakistan, the usefulness of
respective markers in malaria surveillance need to be
further explored.
Circumsporozoite protein (csp): Circumsporozoite
protein is the most abundant polypeptide present on the
sporozoite surface. It exhibits extensive polymorphism
allowing P. vivax to escape the host immune system and
thus sustain itself within a region.11 Therefore, it is the
most widely studied candidate antigen for vaccine
development against pre-erythrocytic stage of the
parasites life cycle.13
Structurally, it is a single copy gene comprising a central
domain of tandem repeated sequences flanked by two
non-repeated conserved sequences (Figure 2). In
Plasmodium vivax, this central domain is composed of a
27 bp element repeated variable number of times. Two
types of non-peptide repeat units; GDRA (A/D) GPQA,
namely VK 210 type and ANGA (G/D) (N/D) QPG,
namely VK 247 type have been observed commonly in
P. vivax.14 A given parasite line can exhibit either VK 210
or VK 247 type.15 However, mixed genetic infection of
both VK 210 and VK 247 is also observed, mostly in
areas of high malaria transmission.6,16,17 Globally, VK
210 is the best adapted variant prevalent in almost all
P. vivax endemic regions.
Studies on the distribution of csp types in neighbour-
ing countries of Pakistan such as India, Iran and
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Figure 2: Organization of Plasmodium vivax circumsporozoite protein gene.
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Afghanistan have shown that genetically distinct csp
variants are circulating within different areas of the same
country for example Kolkata, India reports a prevalence
of VK 210 type (99.3%) while Orissa reports a significant
prevalence of both VK 210 and VK 247 types (39.5%
and 26.3% respectively).18,19 Similarly, reports from
Nangarhar, Afghanistan and Sarbaz/Chabahar, Iran
documents a prevalence of VK 210 type (94.8% and
79.2% respectively).14,19,20 Furthermore, areas such as
Orissa, Herat, Sarbaz/Chabahar have also reported
significant prevalence of mixed genetic infections of
both VK 210 and VK 247 types. Since prevalence of
mutant and mixed infection depends on the trans-
mission intensity of parasite in an area as well as the
transmissibility of Anopheline vector,14,18 therefore,
these studies suggest a high transmission intensity of
P. vivax in their respective areas. Consequently, such
transmission rates put immense host immune pressure
on the parasite leading to natural selection of certain
genotypes in an area.9
Scant data from Pakistan on prevalent csp types has
been reported. Both studies show variable results on
circulating csp types. Study on clinical isolates of P. vivax
from Northern belt of Pakistan (Federally Administered
Tribal Areas) reported the predominance of VK 210 type
(95.7%) in the respective region.19 A larger study from
southern Pakistan, encompassing Sindh and Balochistan
province documented a different pattern with prevalence
of VK 247 type in Balochistan (39%) but not in Karachi
and rural Sindh where prevalence of VK 210 type
(87.4% and 95.2%) was documented.6 Interestingly,
mixed infections were observed in 1.9% and 2.2% of the
total samples in FATA and Karachi only.6,19 These results
provide evidence that similar to its neighbouring
countries; different provinces of Pakistan also harbor
highly diverse csp variant types. Therefore, it is
recommended that larger studies from all the provinces
of Pakistan, especially from high malaria transmission
areas be conducted so that true prevalence of csp
variants could be reported.
The significance of conducting epidemiological studies
on csp types is that it provides a baseline for assessing
the immunological significance of variant types.
Previous studies have shown that degree of antibody
response, induced in an individual, against P. vivax is
dependent on csp type infecting an individual. Several
studies have reported varying response from different
endemic areas. Some studies document better antibody
response against VK 247 type,21 while others report that
VK 210 type induces more potent immune response
than VK 247 type.22 In Pakistan, prospective serological
assays and trials, such as those mentioned above, are
only possible when baseline malaria surveillance
using csp marker is performed on a large scale in
different provinces of Pakistan. Eventually, this baseline
surveillance data and serological studies can provide
guidance in effective malaria vaccine designing.
Merozoite surface protein-1 (msp-1): Merozoite
surface protein-1 is a 200 kDa protein expressed on
P. vivax merozoite surface. During maturation, this
protein undergoes primary and secondary proteolytic
cleavage into four (msp-1 83, 30, 38 and 42 kDa) and
two fragments (msp-1 33 and 19 kDa) respectively.
Functionally, during parasite lifecycle, msp-1 is a critical
antigen involved in red cell invasion. Structurally, msp-1
is, as characterized by monkey adapted P. vivax
cell lines (Belem and Salvadore) show, a mosaic
organization of several variable blocks flanked by
interspecies conserved blocks (ICBs, Figure 3). ICBs
are regions that exhibit dimorphic substitutions and are
highly conserved among Plasmodium species while the
variable blocks exhibit polymorphic substitutions.
Numerous recombination sites within conserved and
polymorphic regions result in frequent switching of
mutations in msp-1, leading to generation of new
alleles.12
Studies on msp-1 allele distribution have been performed
from diverse endemic regions and data indicates that
three msp-1 types, categorized on the basis of structural
similarities with Belem and Salvadore-1 strains are
circulating globally: type-1 (homologous to Belem), type-
2 (homologous to Sal-1) and type-3 (homologous to
both Belem+Sal-1). Type-3 variant is a combination of
Sal-1 like sequence at the 5’ end and Belem like
sequence at the 3’ end and is hypothesized to have
arisen as a result of intragenic recombination between
Sal-1 and Belem.23
Sequencing analysis of msp-1 from different regions of
the same country has shown that genetic fluxes are
common in this gene. As with csp, the prevalence of
msp-1 types is also found to be inconsistent within
neighbouring countries of Pakistan. In Herat and
Nangarhar, Afghanistan, type-2 is the most prevalent
(45.7% and 63%). However, the percent prevalence of
type-1 and type 3 is also high in Herat (26.6% and
26.7% respectively) while type-1 is only 3.7% in
Nangarhar.45 Similarly, in Iran, both Sarbaz and
Chabahar have a moderate prevalence of type-1
(26.6%), type-2 (40%) and type-3 (33.4%).19
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Figure 3: Organization of Plasmodium vivax merozoite surface protein 1 gene.
Limited data have been documented from northern and
southern belt of Pakistan on the prevalent msp-1
types.6,19 Both studies show variability in prevalence
pattern with highly diverse and mixed genetic infections
observed frequently. In the Federally Administered Tribal
Areas (FATA), type-2 and type-3 were observed in
similar prevalence (39.4% and 33.4% respectively) while
type-1 is observed in lower frequency (15.4%) as
compared to the other two types.19 In a study from
Southern Pakistan encompassing Karachi, Balochistan
and rural Sindh, high prevalence of type-2 variants was
observed in all the three areas while mixed infections
were observed frequently in Karachi,6 indicating the high
transmission intensity of P. vivax in both Northern and
Southern Pakistan. Though this knowledge is available,
however, gaps still exist on distribution of msp-1 variants
from other provinces of Pakistan.
The importance of msp-1 knowledge is similar to that of
csp. Serological studies on msp-1 allelic variants and
their role in modulation of immune responses have been
performed globally which have documented that msp-1
induces potent-B and T-cell responses that result in
reduced parasitaemias in animals and primates.
Therefore, msp-1 has been identified as a strong
candidate antigen for vaccine production against
P. vivax.24-26 However, variability in allelic variants
distribution may serve as a significant hindrance in the
deployment and designing of a msp-1 formulated
vaccine. Therefore, malaria surveillance reporting
information on population genetic markers could serve
useful in vaccine designing.
Antimalarial drug resistance in Plasmodium vivax:
Data on genetic diversity serves as a foundation for drug
resistance associated studies as it gives insight about
the pattern of dispersal and stability of multilocus
genotypes. Such information is essential for predicting
and monitoring the usefulness of combining specific
drugs, dispersion of and emergence of drug resistant
parasites.13
Treatment of P. vivax infection is recommended with
chloroquine (CQ).5 However, physicians treating
patients in the public sector are aware of CQ resistance
in P. falciparum and inadvertently correlate the same
pattern for P. vivax. Therefore, the most economical
choice of antimalarial prescribed against P. vivax in
Pakistan is Sulphadoxine-Pyrimethamine (SP).
SP resistance in P. vivax has long been documented
from worldwide and in northern belt of Pakistan.27-34 The
possible factors documented for SP resistance are
untrained laboratory staff that make errors in micro-
scopically diagnosing P. vivax, especially in case of
mixed infections. In such cases, patients are treated with
sub-therapeutic doses of SP,33 unrestricted use of
antifolates, especially Sulphadoxine, for the treatment of
diarrhea, urinary tract and respiratory tract infections in
Pakistan, that may have resulted in development of
intrinsic sulphadoxine resistance in P. vivax, single
and inappropriate combination antimalarial therapy,
prescribed to all who present with fever and chills.34 All
these factors increase the susceptibility of P. vivax to
accumulate SP resistance associated mutations in its
genes in order to survive the environmental drug
pressure thus escalating drug resistance situation.
It is possible that due to the above mentioned factors,
extensive SP resistance has developed in other areas of
Pakistan as well. Thus, monitoring of SP resistance is
important since a large number of treatment failure
cases serve as a human reservoirs of resistant strains.
Further transmission of these resistant strains via
mosquito vectors allows the stable transmission of
resistant genes in an endemic population,26 thus,
weakening implementation of control strategies by
malaria control program.
Genetic markers and mechanism of Sulphadoxine-
pyrimethamine resistance in Plasmodium vivax:
Genetic markers involved in SP resistance in P. vivax
include dihydropteroate synthase (dhps) and dihydro-
folate reductase (dhfr). Both these genes produce key
enzymes for de novo tetrahydrofolate (THF) synthesis
and DNA replication. Briefly, de novo synthesis of
tetrahydrofolate in the parasite begins when folate is
reduced to dihydrofolate by the help of dhps enzyme.
Dihydrofolate is then reduced to tetrahydrofolate
followed by synthesis of methionine, glycine and dTTP
by dhfr enzyme. Parasite DNA synthesis ensues,
resulting in active malarial infection.35
Sulphadoxine-Pyrimethamine acts as antimalarial drug
by inhibiting dhps and dhfr leading to decreased levels
of fully reduced tetrahydrofolate, conversion of glycine,
methionine synthesis, thymidylate levels and subse-
quent arrest of DNA replication (Figure 4).36 However,
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Figure 4: Flowchart showing action of Sulphadoxine-Pyrimethamine on dhfr
and dhps enzymes for termination of parasite DNA synthesis.
P. vivax develop resistance against SP via accumulation
of Single Nucleotide Polymorphisms (SNPs) in genes
coding for dhps and dhfr.37 SNP is a DNA sequence
variation (mutation) that changes single nucleotides in
the genome consequently leading to change in the
amino acid sequence (codon) and resulting in
production of a different protein. A conformational
change in the active binding site of enzymes occurs,
thus, affecting drug binding.38 In P. vivax, these SNPs
result in decreased SP accommodation, binding and
entry thus, making SP ineffective.39 DNA synthesis
continues and a pool of drug resistant strains is
maintained in a region.
Studies have shown that SP is useful only against wild
type or single mutated alleles. Presence of double, triple,
quadruple mutations (accumulation of multiple SNPs) in
major binding sites for SP i.e. codon positions 382, 383,
512, 553, 585 in dhps and 33, 50, 57, 58, 61, 117, 173
in dhfr,28,29,40 is indicative of emergence of drug
resistance making SP defunct for further use against
P. vivax. Other novel SNPs at different codon positions
in P. vivax have also been reported. However, their role
in SP drug resistance is yet to be established.
Prevalence of SP resistance has been documented
extensively from the neighbouring countries of Pakistan.
Afghanistan and Iran have reported prevalence of wild
type and double mixed mutant alleles of dhfr while
limited mutations of dhps have been documented in both
the regions.16,40 India, on the other hand, reports
extensive mutations (upto quadruple) in both dhfr and
dhps implying that SP pressure is high in India
compared to its neighbours.27,28,30 From Pakistan, two
studies, one from FATA region and other from Bannu
district,32,33 have been performed contributing to the
data base. Both studies report limited mutations in both
dhfr and dhps gene. However, limitations with respect to
sampling area (Afghan refugee areas) were inherent in
these studies as the issue of cross border migration and
its role in prevalence of drug resistance needs to be
taken into consideration.
Therefore, the main concern for researchers, at this
time, is to gather and analyze data, from different
regions of Pakistan, so that Malaria Control Program,
Pakistan can map the extent and existence of SP
resistance. Formulation of rational policies is dependent
on these baseline studies, so that the spread of drug
resistance can be controlled.
DISCUSSION
Baseline epidemiological studies on P. vivax population
structure and drug resistance patterns are the mainstay
of research and contribute greatly in understanding as
well as controlling P. vivax infection effectively. It also
allows researchers to estimate the transmission intensity
of the parasite within an area so that rational control
measures can be undertaken.
In Pakistan, limited data is available on circulating geno-
types and drug resistance. Therefore, it is suggested
that large scale studies be undertaken so that prevalent
genotypes of csp and msp-1 can be identified. The
significance of detecting prevalent genotypes is in the
development of effective vaccine. csp and msp-1 based
vaccine formulations has been tested extensively in
malaria endemic regions of Central and South
America.22,26,41-43 Interesting results with potent immune
responses and parasitaemia clearance have been
observed in animal studies. However, these studies
have been conducted on sera obtained from individuals
residing in the respective areas and the results observed
cannot be extrapolated for Pakistani population. The
immune responses in every population are distinct
depending on both host, environment and parasite
factors and, therefore, it is possible that the vaccines
developed may not be effective against P. vivax variants
circulating in Pakistan. Therefore, large scale studies,
primarily on P. vivax genotypes and secondarily on
serological studies is recommended. Once the immune
response patterns against P. vivax are understood,
animal studies and eventual field trials can be
performed. The entire spectrum of P. vivax research is
thus based on the foundation of circulating genotypes. 
The knowledge on drug resistance patterns serve as a
basis of malaria control. Since, no vaccines are currently
available; the main source of control is via anti-malarial
drugs. However, with reports of extensive accumulation
of resistance associated mutations in P. vivax, this form
of control seems to be reaching a point of redundancy.
Newer and better formulations with combination drugs
are recommended for malaria control. However, task of
priority from malaria endemic regions is extensive
reporting of drug resistance data on P. vivax. This will
help in mapping and monitoring the extent of drug
resistance that may possibly have developed in P. vivax.
Once this baseline data is available, WHO and the
National Malaria Control Programs will be able to
develop and implement rational drug policies with
respect to the regions.
CONCLUSION
Lack of genetic diversity and drug resistance data are
hindering the control of Plasmodium vivax transmission
in Pakistan. Evidence based research is needed which
will enable understanding of population structure and
prevalence of resistance so that effective control
strategies may be developed and implemented.
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